Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 33

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 33
---
. Final executive compensation decisions reflect a variety of factors, including each executive’s experience, performance rating, the relative importance of the executive’s role within the organization, as well as where each executive’s pay level falls relative to the market data. In order to evaluate the level of compensation for our named executive officers for 2024, our Compensation Committee, using information provided by Deloitte, established a peer group of publicly traded companies in the biopharmaceutical and biotechnology industries based on a balance of the following criteria:

| • | companies with comparable market capitalizations (i.e., in the range of $696 million to $2,859 million); and |

| • | companies with headcounts between 36 to 236 employees. |

Our 2024 peer group is comprised of the following companies in the biopharmaceutical and biotechnology industries:

| Immunovant, Inc.              |     | Bicycle Therapeutics plc   |
| Acelyrin, Inc.                |     | Rapt Therapeutics, Inc.    |
| Dice Therapeutics, Inc.       |     | Vera Therapeutics, Inc.    |
| Verona Pharma plc             |     | Pharvaris N.V.             |
| Summit Therapeutics Inc.      |     | Aclaris Therapeutics, Inc. |
| Protagonist Therapeutics Inc. |     |                            |

21

TABLE OF CONTENTS

Key Elements of Compensation Base Salary Each named executive officer’s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our Compensation Committee taking into account each individual’s role, responsibilities, skills and experience. Base salaries for our named executive officers are reviewed annually by our Compensation Committee and adjusted from time to time, to realign salaries with market levels after taking into account individual responsibilities, performance and experiences. For 2024, base salary increases for the NEOs were increased 5% after consideration of the foregoing factors. The 2024 and 2023 base salaries of our NEOs as of December 31 stof each year are set forth in the table below. Amounts were converted to U.S. Dollars (USD) from Swiss Francs (CHF) using the exchange rate applicable as of December 31, 2024 (1.1049 USD to 1 CHF):

| Name                      |     | 2024 Base 
    Salary |     | 2023 Base 
    Salary |     | Percentage 
 Change     |
| Dr. Jorge Santos da